drugset / Trial / NCT02562430

Neurobiological Underpinnings of Placebo Response in Depression

NCT02562430

Phase 4 Completed 76 enrolled Massachusetts General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

In summary, the proposed research is novel with respect to design, technology, and its multi-level integration probing psychological and neurobiological constructs assumed to be crucially implicated in placebo response and has significant clinical and research implications for the future. Specifically, the future implications include: 1) identification of biomarkers and biosignatures of placebo responders, 2) new possibilities to understanding and manipulating the system, 3) possibly decreasing or eliminating a major confounder in clinical trials and drug development, and 4) refining treatments with novel drugs that decrease (in clinical trial) or increase (in clinical practice) the placebo response.

Timeline

Start
2016-08
Primary completion
2022-08
Completion
2022-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified

Indications